Veradermics, Incorporated (NYSE:MANE) Stock Has Consensus Price Target of $153.00 According to Brokerages

Posted by Brian Himes on Sep 28th, 2026

Veradermics, Incorporated (NYSE:MANE – Get Free Report) has received an average recommendation of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $153.00.

Several brokerages recently weighed in on MANE. Needham & Company LLC upped their price target on Veradermics from $136.00 to $164.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Lifesci Capital initiated coverage on Veradermics in a research report on Tuesday, June 16th. They set an “outperform” rating and a $135.00 price objective for the company. B. Riley Financial assumed coverage on shares of Veradermics in a report on Wednesday, July 15th. They set a “buy” rating and a $170.00 target price on the stock. Wall Street Zen raised shares of Veradermics from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, UBS Group set a $170.00 price target on shares of Veradermics in a research note on Wednesday, July 15th.

View Our Latest Stock Analysis on Veradermics

Insider Buying and Selling at Veradermics

In other Veradermics news, CEO Reid Alexander Waldman sold 67,500 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $107.86, for a total transaction of $7,280,550.00. Following the completion of the transaction, the chief executive officer owned 170,824 shares of the company’s stock, valued at approximately $18,425,076.64. This trade represents a 28.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director John Childs sold 100,000 shares of Veradermics stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $107.12, for a total transaction of $10,712,000.00. Following the transaction, the director owned 194,117 shares of the company’s stock, valued at $20,793,813.04. The trade was a 34.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 961,000 shares of company stock worth $103,120,220 in the last ninety days.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Arizona State Retirement System purchased a new stake in shares of Veradermics in the second quarter worth $524,000. Wellington Management Group LLP purchased a new position in shares of Veradermics in the 2nd quarter worth about $8,425,000. Seven Fleet Capital Management LP purchased a new position in shares of Veradermics in the 2nd quarter worth about $9,835,000. Bamco Inc. NY boosted its stake in Veradermics by 284.8% in the 2nd quarter. Bamco Inc. NY now owns 229,581 shares of the company’s stock worth $28,225,000 after purchasing an additional 169,913 shares in the last quarter. Finally, Montanova Capital LLC purchased a new stake in Veradermics during the 2nd quarter valued at about $512,533,000.

Veradermics Price Performance

Shares of MANE opened at $117.13 on Monday. The company has a 50-day simple moving average of $106.38 and a two-hundred day simple moving average of $96.34. The firm has a market capitalization of $4.89 billion and a PE ratio of -61.65. Veradermics has a one year low of $32.00 and a one year high of $131.24.

Veradermics (NYSE:MANE – Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.58) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.58). Analysts expect that Veradermics will post -2.74 EPS for the current fiscal year.

Veradermics Company Profile

(Get Free Report)

Veradermics, Inc is a dermatology-focused biopharmaceutical company developing and commercializing therapies for conditions affecting the skin, hair and nails. The company’s research and development activities target common and underserved dermatologic diseases, with an emphasis on treatments that may offer alternatives to existing therapies.

Veradermics is advancing a pipeline of dermatology product candidates across multiple stages of development, including treatments for hair loss and other skin disorders.